Special Drug Use-Results Survey for ZYTIGA Tablets 250 mg (Long-term Use)

Special Drug Use-Results Survey for ZYTIGA Tablets 250 mg (Long-term Use) - Special Drug Use-Results Survey for ZYTIGA Tablets 250 mg (Long-term Use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015894

Enrollment

420

Registered

2014-12-15

Start date

2014-09-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: CRPC patients who are treated with ZYTIGA for the first time

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness(PSA Response rate)	—

Secondary

Measure	Time frame
Effectiveness(Overall survival)	—

Countries

Japan

Contacts

Public ContactSayuri Harada

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

SHarada8@its.jnj.com03-4411-5874

Outcome results